A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis (FILAXOS)
Status: Recruiting
Location: See all (26) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY
This is a prospective, multicenter, observational, non-interventional study (NIS) in patients with Multiple Sclerosis (MS) and routinely assessed serum neurofilament light (sNfL) values in Germany
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 99
Healthy Volunteers: f
View:
⁃ Participants eligible for inclusion in this study must meet all the following criteria:
• Written informed consent must be obtained before participation in the study.
• RMS patients aged 18 or older.
• Treated in label with EU-approved DMTs for MS category 1 according to current guidelines (Hemmer et al 2023) for at least the last 3 months.
• Presence of a sNfL test result from a commercially available test not older than 3 months.
Locations
Other Locations
Germany
Novartis Investigative Site
RECRUITING
Bad Homburg
Novartis Investigative Site
RECRUITING
Bad Krozingen
Novartis Investigative Site
RECRUITING
Bamberg
Novartis Investigative Site
RECRUITING
Bergneustadt
Novartis Investigative Site
RECRUITING
Berlin
Novartis Investigative Site
RECRUITING
Berlin
Novartis Investigative Site
RECRUITING
Berlin
Novartis Investigative Site
RECRUITING
Bielefeld
Novartis Investigative Site
RECRUITING
Bogen
Novartis Investigative Site
RECRUITING
Duisburg
Novartis Investigative Site
RECRUITING
Düsseldorf
Novartis Investigative Site
RECRUITING
Essen
Novartis Investigative Site
RECRUITING
Hamburg
Novartis Investigative Site
RECRUITING
Itzehoe
Novartis Investigative Site
RECRUITING
Leipzig
Novartis Investigative Site
RECRUITING
Meerbusch
Novartis Investigative Site
RECRUITING
München
Novartis Investigative Site
RECRUITING
München
Novartis Investigative Site
RECRUITING
Regensburg
Novartis Investigative Site
RECRUITING
Remscheid
Novartis Investigative Site
RECRUITING
Salzatal Ot Salzmuende
Novartis Investigative Site
RECRUITING
Siegen
Novartis Investigative Site
RECRUITING
Stuttgart
Novartis Investigative Site
RECRUITING
Sundern Hachen
Novartis Investigative Site
RECRUITING
Tirschenreuth
Novartis Investigative Site
RECRUITING
Untermeiting
Contact Information
Primary
Novartis Pharmaceuticals
novartis.email@novartis.com
+41613241111
Backup
Novartis Pharmaceuticals
Time Frame
Start Date: 2024-10-23
Estimated Completion Date: 2027-09-16
Participants
Target number of participants: 900
Treatments
Ofatumumab
Patients who have received treatment with category 1 DMTs and decided to switch to ofatumumab
Category 1 DMTs
Patients who continued with DMT category 1 treatment. According to local treatment guidelines, DMT category 1 include dimethylfumarate/diroximelfumarate, glatirameroids, Interferon beta and teriflunomide.
Related Therapeutic Areas
Sponsors
Leads: Novartis Pharmaceuticals